CDH13
Basics
Aliases:
This biomarker is also known as:- H-cadherin (heart),
- heart-cadherin,
- P105,
- T-cadherin,
- truncated-cadherin,
- T-cad,
- cadherin 13,
- H-cadherin,
Description…
CDH13 is a member of the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region but, unlike the typical cadherin superfamily member, lacks the highly conserved cytoplasmic region. This particular cadherin is a putative mediator of cell-cell interaction in the heart and may act as a negative regulator of neural cell growth. The gene locus is hypermethylated or deleted in breast, ovarian and lung cancers.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Genomic |
| Short Name: |
Organs
The following organs have data associated with this biomarker…
Esophagus
Attributes
| Phase: | Two |
|---|---|
| QA State: | Accepted |
Overview
Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
Performance Comment
Levels of CDH13 hypermethylation have been shown to discriminate esophageal adenocarcinoma from esophageal squamous cell carcinoma and normal esophagus. CDH13 is also being investigated as a biomarker for progression from Barrett's esophagus to esophageal adenocarcinoma. Studies are ongoing.
Supporting Study Data
The following studies/protocols provide evidence supporting CDH13 indications for the Esophagus…
Barrett's Esophagus Methylation Profiles
We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For CDH13, AUC (95% confidence interval) was 0.515 (0.409, 0.622). | 0.0 | 0.0 | 0.0 |
Decision Rule
PMID:18729198
Additional Study-Specific Protocols
Study-Specific Publications
- Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Lung
Attributes
| Phase: | One |
|---|---|
| QA State: | Under Review |
Overview
Performance Comment
Supporting Study Data
The following studies/protocols provide evidence supporting CDH13 indications for the Lung…
No supporting studies or protocols found.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
Publications
- Methylation pattern of CDH13 gene in digestive tract cancers.
- Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.
- Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
